Birch Hill Investment Advisors LLC Has $25.61 Million Stake in Edwards Lifesciences Co. (NYSE:EW)

Birch Hill Investment Advisors LLC lifted its stake in shares of Edwards Lifesciences Co. (NYSE:EW) by 0.8% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 388,129 shares of the medical research company’s stock after purchasing an additional 3,085 shares during the period. Birch Hill Investment Advisors LLC owned approximately 0.06% of Edwards Lifesciences worth $25,613,000 at the end of the most recent reporting period.

A number of other large investors also recently modified their holdings of the stock. Park Avenue Securities LLC boosted its position in Edwards Lifesciences by 0.5% during the second quarter. Park Avenue Securities LLC now owns 23,484 shares of the medical research company’s stock worth $2,169,000 after purchasing an additional 108 shares during the period. City State Bank increased its stake in shares of Edwards Lifesciences by 16.5% in the second quarter. City State Bank now owns 917 shares of the medical research company’s stock worth $85,000 after buying an additional 130 shares during the period. Chapin Davis Inc. increased its stake in shares of Edwards Lifesciences by 1.7% in the first quarter. Chapin Davis Inc. now owns 8,548 shares of the medical research company’s stock worth $817,000 after buying an additional 140 shares during the period. Valley National Advisers Inc. boosted its holdings in Edwards Lifesciences by 6.0% in the first quarter. Valley National Advisers Inc. now owns 2,677 shares of the medical research company’s stock valued at $255,000 after acquiring an additional 152 shares in the last quarter. Finally, Choreo LLC boosted its holdings in Edwards Lifesciences by 4.1% in the first quarter. Choreo LLC now owns 3,840 shares of the medical research company’s stock valued at $367,000 after acquiring an additional 153 shares in the last quarter. 79.46% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

EW has been the topic of a number of analyst reports. Oppenheimer reiterated an “outperform” rating and issued a $90.00 price target on shares of Edwards Lifesciences in a research note on Thursday, September 12th. Daiwa Capital Markets upgraded Edwards Lifesciences from a “neutral” rating to an “outperform” rating in a research note on Wednesday, July 31st. Bank of America downgraded Edwards Lifesciences from a “buy” rating to a “neutral” rating and cut their price objective for the company from $105.00 to $75.00 in a research note on Thursday, July 25th. Wolfe Research upgraded Edwards Lifesciences from an “underperform” rating to a “peer perform” rating in a research note on Monday, July 29th. Finally, Deutsche Bank Aktiengesellschaft lowered their target price on Edwards Lifesciences from $103.00 to $85.00 and set a “buy” rating for the company in a research report on Thursday, July 25th. Seventeen equities research analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, Edwards Lifesciences presently has an average rating of “Hold” and an average target price of $75.77.

Insider Transactions at Edwards Lifesciences

In other news, VP Daveen Chopra sold 1,250 shares of the company’s stock in a transaction dated Tuesday, August 20th. The stock was sold at an average price of $69.95, for a total transaction of $87,437.50. Following the completion of the transaction, the vice president now directly owns 29,333 shares of the company’s stock, valued at approximately $2,051,843.35. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. In other Edwards Lifesciences news, VP Donald E. Bobo, Jr. sold 5,000 shares of the stock in a transaction that occurred on Wednesday, September 11th. The stock was sold at an average price of $66.77, for a total transaction of $333,850.00. Following the completion of the sale, the vice president now directly owns 46,936 shares of the company’s stock, valued at approximately $3,133,916.72. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, VP Daveen Chopra sold 1,250 shares of the stock in a transaction that occurred on Tuesday, August 20th. The stock was sold at an average price of $69.95, for a total value of $87,437.50. Following the sale, the vice president now directly owns 29,333 shares of the company’s stock, valued at $2,051,843.35. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 11,250 shares of company stock valued at $751,688. 1.29% of the stock is currently owned by corporate insiders.

Edwards Lifesciences Price Performance

Shares of NYSE EW opened at $68.13 on Friday. The stock’s 50-day moving average is $67.13 and its two-hundred day moving average is $80.08. The company has a debt-to-equity ratio of 0.08, a current ratio of 3.71 and a quick ratio of 2.87. Edwards Lifesciences Co. has a 1-year low of $58.93 and a 1-year high of $96.12. The company has a market cap of $41.06 billion, a price-to-earnings ratio of 29.37, a price-to-earnings-growth ratio of 2.83 and a beta of 1.13.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings data on Wednesday, July 24th. The medical research company reported $0.70 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.69 by $0.01. The business had revenue of $1.63 billion during the quarter, compared to analysts’ expectations of $1.65 billion. Edwards Lifesciences had a return on equity of 22.35% and a net margin of 24.55%. The business’s quarterly revenue was up 6.7% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.66 EPS. Analysts forecast that Edwards Lifesciences Co. will post 2.71 EPS for the current fiscal year.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.